Korean Market
EXCH
OLIPASS
★

OLIPASS Receives USD 328K R&D Payment from Vanda Pharmaceuticals – Recognized as R&D Revenue, Improving Profitability Outlook

 
EXCH
OLIPASS
★

OLIPASS Receives USD 602,000 from Vanda Pharmaceuticals for Joint R&D - Revenue Recognition Expected to Boost Earnings

 
EXCH
OLIPASS
★

Olipass Receives USD 353,995 from Vanda Pharmaceuticals for Joint R&D - Modest Positive Cash Inflow

 
EXCH
OLIPASS
★

OliPass Discloses Option Exercise Fee and Extends Contract with Vanda Pharma for Joint R&D on Rare Disease and Immuno-Oncology Drugs – Positive Collaboration Continuation

 
PERI
OLIPASS
★★★★★

Olipass Files for Reorganization amid Complete Capital Erosion and Delisting Risk

 
EXCH
OLIPASS
★★★★

Quarterly Sales Shortfall of 300 Million Won, Due to R&D and Product Sales Sluggishness

 
EXCH
OLIPASS
★★

Olipass Faces Additional Delisting Reason; Awaiting Litigation Outcome

 
EXCH
OLIPASS
★★★★★

Decision on Property Preservation and Comprehensive Injunction Order

 
EXCH
OLIPASS
★★★★★

Olipass Files for Rehabilitation and Delisting Market Guidance

 
MATR
OLIPASS
★★★★

Olipass Files for Court Receivership

 
EXCH
OLIPASS
★★★

Extension of Postponement for R&D Expense Receipt from Vanda Pharmaceuticals

 
EXCH
OLIPASS
★

Extension of Confidentiality Period for R&D Payment from Vanda Pharmaceuticals

 
EXCH
OLIPASS
★

Extension of Confidentiality for R&D Fee from Vanda Pharmaceuticals

 
EXCH
OLIPASS
★

1-Month Extension of Co-Development Contract with Vanda Pharma